Table 1.
Demographic and clinical characteristics of the study cohort compared with all other HCT recipients during the study period
| Characteristic | All HCTs during study period, n (%); N = 1926 | Selected cohort; N = 404 | Unselected cohort; N = 1522* |
|---|---|---|---|
| Age >21 y | 1591 (83) | 358 (89) | 1233 (81) |
| Female sex | 809 (42) | 179 (44) | 630 (41) |
| White | 1430 (74) | 277 (69) | 1153 (76) |
| CMV donor negative, recipient negative | 563 (29) | 57 (14) | 506 (33) |
| HCT comorbidity index† | |||
| Low (0) | 223 (18) | 70 (17) | 153 (18) |
| Intermediate (1-2) | 391 (31) | 133 (33) | 258 (30) |
| High (≥3) | 658 (52) | 201 (50) | 457 (53) |
| Underlying disease | |||
| Acute leukemia | 928 (48) | 195 (48) | 733 (48) |
| Chronic leukemia | 186 (10) | 58 (14) | 128 (8) |
| Lymphoma | 232 (12) | 41 (10) | 191 (13) |
| Nonmalignant | 158 (8) | 24 (6) | 134 (9) |
| Other | 422 (22) | 86 (21) | 336 (22) |
| Higher-risk disease‡ | 394 (20) | 75 (19) | 319 (21) |
| Myeloablative conditioning regimen§ | 683 (35) | 155 (38) | 528 (35) |
| HCT type‖ | |||
| HLA matched | 1392 (72) | 154 (38) | 1,238 (81) |
| HLA mismatched | 302 (16) | 125 (31) | 177 (12) |
| Cord blood | 232 (12) | 125 (31) | 107 (7) |
| Donor related | 703 (37) | 131 (32) | 572 (38) |
| Acute GVHD, grade 3-4¶ | 246 (13) | 46 (11) | 200 (13) |
Unknown data for N patients in the following categories: 89, race; 54, CMV serostatus; 654, HCT comorbidity index.
Based on the HCT comorbidity index.40
Higher-risk disease refers to diagnoses other than acute myeloid leukemia, acute lymphoblastic leukemia, or lymphoma in first remission, chronic myeloid leukemia in chronic phase, and refractory anemia without excess blasts.
Myeloablative regimens included any regimen containing ≥800 cGY total body irradiation, any regimen containing carmustine/etoposide/cytarabine/melphalan (BEAM), or any regimen containing busulfan/cyclophosphamide with or without antithymocyte globulin.
Categories included related and unrelated donors. HLA-matched HCTs included 76 related donors and 78 unrelated donors. HLA-mismatched HCTs included 55 related donors and 70 unrelated donors; this group consisted of 47 haploidentical donors, 76 9/10-matched donors, and 2 8/10-matched donors. All cord blood HCTs were mismatched, and 12 were single unit.
Acute graft-versus-host disease grades were categorized as previously described.41